(Q34710610)

4 August 2017

1 reference

title

Focus on central nervous system neoplasia (English)

1 reference

4 August 2017

0 references

3

J Gregory Cairncross

1 reference

4 August 2017

David N Louis

1

1 reference

4 August 2017

Scott L Pomeroy

series ordinal

2

1 reference

4 August 2017

publication date

1 March 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

1

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

125-128

1 reference

EGFR overexpression and radiation response in glioblastoma multiforme

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Cytogenetics and molecular genetics of childhood brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme?

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

1 reference

7 January 2021

Gliomagenesis: genetic alterations and mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

STI571: a paradigm of new agents for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Medulloblastoma: clinical and biologic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Prediction of central nervous system embryonal tumour outcome based on gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

The developmental biology of brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900040-5

7 January 2021

10.1016/S1535-6108(02)00040-5

Identifiers

DOI

1 reference

4 August 2017

1 reference